ATE253593T1 - Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit - Google Patents

Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit

Info

Publication number
ATE253593T1
ATE253593T1 AT97934467T AT97934467T ATE253593T1 AT E253593 T1 ATE253593 T1 AT E253593T1 AT 97934467 T AT97934467 T AT 97934467T AT 97934467 T AT97934467 T AT 97934467T AT E253593 T1 ATE253593 T1 AT E253593T1
Authority
AT
Austria
Prior art keywords
igsf
domains
fragments
modification
fusion proteins
Prior art date
Application number
AT97934467T
Other languages
English (en)
Inventor
Andreas Plueckthun
Lars Nieba
Annemarie Honegger
Original Assignee
Plueckthun Andreas Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plueckthun Andreas Prof Dr filed Critical Plueckthun Andreas Prof Dr
Application granted granted Critical
Publication of ATE253593T1 publication Critical patent/ATE253593T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT97934467T 1996-07-16 1997-07-16 Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit ATE253593T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111441 1996-07-16
PCT/EP1997/003792 WO1998002462A1 (en) 1996-07-16 1997-07-16 Immunoglobulin superfamily domains and fragments with increased solubility

Publications (1)

Publication Number Publication Date
ATE253593T1 true ATE253593T1 (de) 2003-11-15

Family

ID=8222993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934467T ATE253593T1 (de) 1996-07-16 1997-07-16 Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit

Country Status (7)

Country Link
US (1) US6815540B1 (de)
EP (1) EP0938506B1 (de)
JP (1) JP2000516452A (de)
AT (1) ATE253593T1 (de)
CA (1) CA2267620A1 (de)
DE (1) DE69726003T2 (de)
WO (1) WO1998002462A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
JP2002530080A (ja) * 1998-11-19 2002-09-17 インサイト・ファーマスーティカルズ・インコーポレイテッド 免疫グロブリン・スーパーファミリー・タンパク質
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1817340B1 (de) 2004-11-12 2012-05-16 Xencor, Inc. Fc-varianten mit veränderter bindung zu fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DE602005020972D1 (en) 2004-12-07 2010-06-10 Lonza Ag Rhamnosepromotor-expressionssystem
AU2005313530B2 (en) 2004-12-07 2011-03-10 Lonza Ag Melibiose operon expression system
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
EP2395026B1 (de) 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Verfahren zur Verbesserung eines Antikörpers
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
MX2008013705A (es) 2006-04-28 2008-11-06 Esbatech Ag Anticuerpos que se enlazan al dominio extracelular de la cinasa de linfoma anaplastico del receptor tirosina cinasa.
CA2653661A1 (en) * 2006-05-31 2007-12-06 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008333985B2 (en) 2007-11-30 2015-02-05 Kalobios Pharmaceuticals, Inc. Antibodies to the PcrV antigen of pseudomonas aeruginosa
LT2808343T (lt) 2007-12-26 2019-09-10 Xencor Inc. Fc variantai su pakitusiu prisijungimu prie fcrn
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
KR102095257B1 (ko) * 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
AU2013203477B2 (en) * 2008-06-25 2015-02-12 Novartis Ag Solubility optimization of immunobinders
AU2009264566B2 (en) * 2008-06-25 2014-05-08 Novartis Ag Solubility optimization of immunobinders
HUE047678T2 (hu) * 2008-06-25 2020-05-28 Novartis Ag Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával
JP5856480B2 (ja) * 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102239181A (zh) 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 用于鉴定细胞表面抗原的免疫结合剂的方法
ES2618181T3 (es) * 2009-02-24 2017-06-21 Esbatech, An Alcon Biomedical Research Unit Llc Métodos para identificar inmunoaglutinantes de antígenos de superficie celular
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
US8796425B2 (en) 2009-12-23 2014-08-05 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
EP3164417A1 (de) 2014-07-01 2017-05-10 Pfizer Inc. Bispezifische heterodimere diabodies und verwendungen davon
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
JP7015793B2 (ja) * 2016-05-19 2022-02-03 ウィスコンシン アルムニ リサーチ ファンデイション 生体分子の溶媒接近性および３次元構造を研究するための方法、システムおよび組成物
CN113272322A (zh) * 2018-10-08 2021-08-17 Uab 研究基金会 神经内分泌癌靶向治疗
EP4334333A1 (de) * 2021-05-03 2024-03-13 Agilent Technologies, Inc. Chimäre immunogene und verfahren zur herstellung polyklonaler antikörper gegen spezifische epitope

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions

Also Published As

Publication number Publication date
JP2000516452A (ja) 2000-12-12
WO1998002462A1 (en) 1998-01-22
EP0938506B1 (de) 2003-11-05
DE69726003D1 (de) 2003-12-11
CA2267620A1 (en) 1998-01-22
DE69726003T2 (de) 2004-08-26
EP0938506A1 (de) 1999-09-01
US6815540B1 (en) 2004-11-09

Similar Documents

Publication Publication Date Title
ATE253593T1 (de) Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
WO1999055868A3 (en) Fizz proteins
Bhakdi et al. Isolation of the terminal complement complex from target sheep erythrocyte membranes
CA2068222A1 (en) Monoclonal antibodies
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
Journet et al. Requirement for Both D Domains of the Propolypeptide in von Willebrand Factor Muitimerization and Storage
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
AU2002363465A1 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
WO2002005843A3 (en) Human rrp sequences and methods of use
DE69611896T2 (de) Fusions-DNS-Sequenz, dadurch exprimiertes Fusionsprotein und Verfahren zur Expression dieses Fusionsproteins
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
ZA200007619B (en) New peptide fragments for protein purification.
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
Kumazaki et al. Comparative study on fibers isolated from four R-type pyocins, phage-tail-like bacteriocins of Pseudomonas aeruginosa
WO1999042586A3 (en) Exo1 and exo2, exocytotic proteins
WO2001014536A3 (de) Nukleinsäuremolekül, umfassend eine für ein hämocyanin kodierende nukleinsäuresequenz und mindestens eine intronsequenz
DK1270590T3 (da) Protein, som fremmer overlevelse af stavformede fotoreceptorceller og nucleinsyre kodende herfor
Matsugu et al. Improved antigen detection on western blots
EP1251139A3 (de) Menschliches mindin-ähliches Protein und dafür kodierende Nukleinsäure
EP2050762A3 (de) Neue Polypeptide und für diese kodierende Nukleinsäuren
DK1241251T3 (da) Humant prostasin-lignende protein og nukleinsyrer kodende for samme
EP1247817A3 (de) Menschliches CD-23-ähliches Protein und dafür kodierende Nukleinsäure
EP1241252A3 (de) Menschliches Enteropeptidase-ähnliches Protein und dafür kodierende Nukleinsäure
AU2001294399A1 (en) Heavy chain libraries
EP1241184A3 (de) Menschliches Synaptogyrin-ähnliches Protein und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0938506

Country of ref document: EP

REN Ceased due to non-payment of the annual fee